Dextromethorphan and guaifenesin use must be monitored very carefully in clients with "weak metabolizer" CYP2D6 enzyme levels and patients who're sedated. This combination medication incorporates a huge median toxic dose (TD50) to median effective dose (ED50) ratio (or therapeutic index) in these individuals. 资助维基百科 外观 创建账号 登录 个人工具 创建账号 Ethical https://bitcoinwalletpasswordreco02222.designertoblog.com/61569553/the-5-second-trick-for-dextromethorphan-dxm-for-sale-in-australia